Research programme: antibody therapeutics - GigaGen
Latest Information Update: 09 Oct 2024
Price :
$50 *
At a glance
- Originator GigaGen
- Class Botulinum toxins; Polyclonal antibodies; Recombinant proteins
- Mechanism of Action Botulinum toxin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Botulism; Infections
Most Recent Events
- 03 Oct 2024 GigaGen enters into agreement with Biomedical Advanced Research and Development Authority (BARDA) for development of antibody therapeutics against high-priority toxins and pathogens
- 15 Sep 2022 GigaGen entered into a contract with the U.S. Department of Defense’s (DOD) for development of antibody therapeutics against high-priority toxins and pathogens
- 15 Sep 2022 Early research in Botulism in USA